Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise.
Atrial natriuretic peptide (ANP) controls lipolysis in human adipocytes. Lipid mobilization is increased during repeated bouts of exercise, but the underlying mechanisms involved in this process have not yet been delineated. The relative involvement of catecholamine- and ANP-dependent pathways in the control of lipid mobilization during repeated bouts of exercise was thus investigated in subcutaneous adipose tissue (SCAT) by microdialysis. The study was performed in healthy males. Subjects performed two 45-min exercise bouts (E1 and E2) at 50% of their maximal oxygen uptake separated by a 60-min rest period. Extracellular glycerol concentration (EGC), reflecting SCAT lipolysis, was measured in a control probe perfused with Ringer solution and in two other probes perfused with either Ringer plus phentolamine (alpha(1/2)-AR antagonist) or Ringer plus both phentolamine and propranolol (beta-AR antagonist). Plasma epinephrine, plasma glycerol, and EGC were 1.7-, 1.6-, and 1.2-fold higher in E2 than in E1, respectively. Phentolamine potentiated exercise-induced EGC increase during E2 only. Propranolol reduced the lipolytic rate during both E1 and E2 compared with the probe with phentolamine. Plasma ANP concentration increased more during E2 than during E1 and was correlated with the increase in EGC in the probe containing phentolamine plus propranolol. The results suggest that ANP is involved in the control of lipolysis during exercise and that it contributes to stimulation of lipolysis during repeated bouts of exercise.
Moro
Cédric
C
Franco-Czech Laboratory for Clinical Research on Obesity, French Institute of Health and Medical Research (INSERM U586), Toulouse, France. moro@cict.fr
Polak
Jan
J
Hejnova
Jindra
J
Klimcakova
Eva
E
Crampes
François
F
Stich
Vladimir
V
Lafontan
Max
M
Berlan
Michel
M
D000273:Adipose Tissue / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism; D000328:Adult; D009320:Atrial Natriuretic Factor / Q000097:blood* / Q000502:physiology; D001786:Blood Glucose / Q000378:metabolism; D002395:Catecholamines / Q000097:blood; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D004837:Epinephrine / Q000097:blood; D015444:Exercise / Q000502:physiology*; D045604:Extracellular Fluid / Q000187:drug effects / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005990:Glycerol / Q000097:blood / Q000378:metabolism; D013006:Growth Hormone / Q000097:blood; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D007328:Insulin / Q000097:blood; D008066:Lipolysis / Q000502:physiology*; D008297:Male; D017551:Microdialysis; D009638:Norepinephrine / Q000097:blood; D010646:Phentolamine / Q000494:pharmacology; D010807:Physical Endurance / Q000502:physiology*; D011433:Propranolol / Q000494:pharmacology; D012039:Regional Blood Flow / Q000502:physiology
D001786:Blood Glucose; D002395:Catecholamines; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D009320:Atrial Natriuretic Factor; D013006:Growth Hormone; D011433:Propranolol; D000242:Cyclic AMP; D006152:Cyclic GMP; D005990:Glycerol; D009638:Norepinephrine; D004837:Epinephrine; D010646:Phentolamine